Delphia (USA)’s Pliant Therapeutics PLRX Stock Holding History

Delphia (USA)’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-17,177	Closed	-$138K	–	390
2022 Q2	$138K	Buy	+17,177	New	+$110K	0.1%	320

Other funds holding PLRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Delphia (USA)'s PLRX Position: Q3 2022 in Review

Delphia (USA) sold out of Pliant Therapeutics (PLRX) in Q3 2022, closing a stake of 17,177 shares — an estimated $138K sold.

Delphia (USA) first reported a position in PLRX in Q2 2022 and held it in 1 quarter. The position peaked at $138K in Q2 2022. 110 funds tracked by Wall St. Rank hold PLRX as of Q3 2022.

Delphia (USA) reported no remaining Pliant Therapeutics position as of Q3 2022 after selling out during the quarter.
Delphia (USA) sold 17,177 Pliant Therapeutics shares in Q3 2022, an estimated $138K.
Delphia (USA) first reported a position in Pliant Therapeutics in Q2 2022 and held it in 1 quarter.
Delphia (USA)'s Pliant Therapeutics position peaked at $138K in Q2 2022.
110 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.